Generation and Characterization of a Preventive and Therapeutic HPV DNA Vaccine

Abstract (Set) Cervical cancer is one of the most common cancers in women worldwide. Persistent infection with human papillomavirus (HPV) is considered to be the etiological factor for cervical cancer. Therefore, an effective vaccine against HPV infections may lead to the control of cervical cancer. An ideal HPV vaccine should aim to generate both humeral immune response to prevent new infections as well as cell-mediated immunity to eliminate established infection or HPV-related disease. JHU scientists have generated a potential preventive and therapeutic HPV DNA vaccine using human calreticulin (CRT) linked to HPV16 early and late proteins. Vaccination with the novel vaccine induced a potent E6/E7-specific CD8+ T cell immune response, resulting in a significant therapeutic effect against E6/E7 expressing tumor cells. In addition, vaccination with the novel vaccine generated significant late protein neutralizing antibody responses, protecting against HPV-16 pseudovirion infections. Thus, the novel HPV DNA vaccine is capable of generating potent preventive and therapeutic effects in vaccinated mice. The data has significant clinical implications. Description (Set) Proposed Use (Set) The invention can be used to generate a preventative and therapeutic HPV DNA vaccine.

Inventor(s): Wu, T.C. ,Hung, Chien-Fu,Roden, Richard B. S.

Type of Offer: Licensing



« More Medical Patents

---